|
From: OncLive <edigest@onclive.com>
Sent: <Day, Month xx, 2020>
To: <<Email Address>>
Subject: Live Broadcast Registration Confirmation: A New First-Line Combination for Advanced Renal Cell Carcinoma
No Images? Click here
|
|
|
Dear [Full Name],
We are pleased to confirm your registration to view this live broadcast to gain an expert perspective on the changing therapeutic landscape and learn about a new first-line combination approach for patients with advanced renal cell carcinoma.
Thank you for your participation!
Date: [Month/Day/20]
Time: [XX:XXpm]
|
|
|
This program is intended for US Healthcare Professionals including: Oncologists, NPs, PAs, RNs, Pharmacists. Program is not intended for non-healthcare professionals, including guests or spouses.
|
|
|
|
|
Daniel James George, MD
Professor of Medicine and Surgery
Director of GU Oncology
Co-Leader, DCI Center for Prostate & Urologic Cancers
Duke University Medical Center
|
|
|
|
Ulka Vaishampayan, MD
Professor of Medicine
Division of Hematology/Oncology
University of Michigan
|
|
|
|
Sumanta Kumar Pal, MD
Clinical Professor
Department of Medical Oncology & Experimental Therapeutics
City of Hope
|
|
|
|
In this Live Broadcast Dr. George, Dr. Vaishampayan, and Dr. Pal will:
|
|
|
|
|
Explore key efficacy and safety data for a new first-line combination regimen
|
|
|
|
|
|
Provide expert perspectives on clinical trial data
|
|
|
|
|
|
Share clinical insights through a live Q&A
|
|
|
|
|
|
|
CA-1716 01/21
This program is not certified for Continuing Medical Education credit.
This program is intended for US Healthcare Professionals including: Oncologists, NPs, PAs, RNs, Pharmacists. Program is not intended for non-healthcare professionals, including guests or spouses.
|
|
|
|
|
|
OncLive® – an MJH Life Sciences™ brand
Copyright 2021 © Intellisphere, LLC
2 Clarke Dr | Suite 100 | Cranbury, NJ | 08512
Preferences | Unsubscribe
|
|
|
